Developer docs
API playgroundTry for free, no card

Search company profiles

Sepset Biosciences

Full company profile

uuid000bw6a

Namestring
Sepset Biosciences
Legal namestring
Sepset Biosciences Inc.
Websiteurl
sepset.ca
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Sepset Biosciences Inc. is a privately held molecular diagnostics company headquartered in Victoria, British Columbia, that is developing a first-in-class blood-based in vitro diagnostic assay called Sepset-ER for early risk assessment of sepsis. The test detects a proprietary gene expression signature based on the dysfunctional immune response (cellular reprogramming, also termed endotoxin tolerance) rather than the presence of a pathogen, identifying patients at high risk of developing sepsis and associated organ failure within approximately 1-2 hours of blood draw at first clinical presentation in the emergency room or intensive care unit. The technology was discovered by Drs. Robert Hancock and Olga Pena at the University of British Columbia, patented in 18 countries (with grants confirmed in Europe, China, and Hong Kong), and validated across more than 3,000 patients in prospective multi-center international clinical studies, with the most recent validation published in Nature Communications 16(1):4442 (Malic et al., 2025).

The company's core technical components are a host-response gene-expression signature, a proprietary machine learning classifier, and a centrifugal microfluidics platform intended for bedside use. Sepset operates as a clinical-stage R&D company with 11-50 employees and a four-person executive team led by founder/CEO Dr. Robert Hancock. Its technologies have not yet received marketing authorization and are not currently available for purchase. Sepset is preparing for 510(k) regulatory clinical studies and plans to commercialize exclusively via out-licensing its gene signature to diagnostic companies that will perform the regulatory trials and market the test in their respective countries; out-licensees are already conducting trials across geographies covering roughly one third of the world's population, with Sepset retaining partial ownership and royalty rights.

Sepset was founded in 2016 as a spinout from the Centre for Drug Research and Development (CDRD, now adMare) and UBC, and is majority-owned by publicly listed parent Asep Medical Holdings Inc. (CSE). Revenue has not been disclosed and the company remains pre-commercial, addressing a market opportunity anchored by an estimated $24 billion annual U.S. cost of treating sepsis and 49 million global sepsis hospitalizations per year.

Short descriptiontext

Sepset Biosciences is a pre-commercial molecular diagnostics company developing the Sepset-ER blood-based gene expression assay for rapid (~1 hour) sepsis risk assessment in hospital emergency rooms and intensive care units, commercializing via out-licensing to diagnostic partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, sepsis detection, gene expression assay, in vitro diagnostics, blood-based diagnostics
Industry2 codes
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Out-licensing and Royalty Agreements
TypeLicensing Royalties
Description

Sepset has out-licensed its technology to companies performing regulatory trials and marketing the test in countries representing one third of the world's population. Sepset benefits through partial ownership of these companies and royalty agreements.

sepset.ca
2In vitro Diagnostic Test Sales
TypeOne Time License
Description

Once regulatory approval is obtained, the company plans to commercialize its Sepset-ER blood-based gene expression assay through licensing partners for hospital and clinical use in ER and ICU settings.

sepset.ca
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Sepset-ER
Description

Blood-based gene expression assay test for early risk assessment of sepsis in emergency rooms and intensive care units. Provides results within approximately 1 hour after taking a blood sample.

sepset.ca
Core offering1 text field

Sepset Biosciences is developing the Sepset-ER blood-based gene expression assay, a first-in-class in vitro diagnostic test that detects a unique sepsis gene expression signature based on the host's dysfunctional immune response (cellular reprogramming/endotoxin tolerance). The test provides rapid sepsis risk assessment within approximately 1-2 hours of blood sampling in emergency rooms and intensive care units, enabling earlier clinical intervention. The company plans to commercialize through out-licensing its gene signature to diagnostic companies that will perform regulatory trials and market the test.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sepset Biosciences is a medical diagnostic company with a single primary product offering: the Sepset-ER blood-based gene expression test. The company is in advanced development stages preparing for 510(k) regulatory clinical studies and commercialization. The test provides rapid (~1-2 hours) sepsis risk assessment by detecting a proprietary gene expression signature from blood samples, enabling physicians to make critical early treatment decisions for patients in the ER and ICU. The technology was validated on more than 3,000 patients and has been out-licensed to companies performing regulatory trials in countries representing one-third of the world's population.

Product and service1 record
1Sepset-ER Test
CategoryIn vitro diagnostic assay / Sepsis risk assessment
Description

A first-in-class blood-based gene expression assay for the early and rapid risk assessment of sepsis. The test detects a unique sepsis gene expression signature based on dysfunctional immune response (cellular reprogramming/endotoxin tolerance) to identify patients at high risk of developing sepsis and organ failure within approximately 1-2 hours of blood sampling in the emergency room or intensive care unit. The test is intended for hospital and clinical use to enable earlier intervention and reduce mortality.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Out-Licensed Diagnostic Companies
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

The test has been out-licensed to companies performing regulatory trials and marketing the test in countries representing one third of the world's population. Sepset benefits through partial ownership of these companies and royalty agreements.

sepset.ca
2University of British Columbia (UBC)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sepset's technology is based on extensive ground-breaking work led by Dr. Robert Hancock, Professor of Microbiology and Immunology and Director of the Centre for Microbial Diseases and Immunity Research at UBC. The spinout was a collaboration between CDRD and UBC.

sepset.ca
3Dr. John Boyd (St. Paul's Hospital)
Strategic tierMinorTypeOthers
Description

Dr. John Boyd, an emergency room physician at Vancouver's St. Paul's Hospital, serves as an advisor to Sepset, providing clinical perspective on the diagnostic test's utility in real-world ER settings.

sepset.ca
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Sepset welcomes opportunities to collaborate with diagnostic companies that wish to transfer its gene signature onto a clinical platform. The company actively seeks new partnerships to expand distribution of the technology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Prenosis (which merged with Inflammatix) is developing host-response diagnostics for acute infections and sepsis, including the Sepsis ImmunoScore, leveraging AI on gene-expression and clinical biomarker data. Directly comparable to Sepset on technology category (host-response), target use case (early sepsis recognition) and go-to-market (partnership with hospital systems and IVD platforms).

TypeDirect peer
Description

T2 Biosystems markets T2Bacteria and T2Candida, FDA-cleared direct-from-blood molecular diagnostics for bloodstream infections. While pathogen-detection based rather than host-response, T2 addresses the same sepsis-workup bottleneck (speed of pathogen ID vs. blood culture) and competes for the same hospital diagnostic budget.

TypeDirect peer
Description

Immunexpress developed SeptiCyte RAPID, an FDA-cleared blood-based host-response gene-expression test that distinguishes sepsis from SIRS in ICU patients. It is the closest functional analog to Sepset-ER - same biology (host immune-response gene signature), same use case (sepsis risk stratification), and same planned customer (ER/ICU physicians).

TypeDirect peer
Description

Accelerate Diagnostics develops rapid identification and antimicrobial susceptibility testing (ID/AST) systems for bloodstream and other serious infections. Its Accelerate Pheno system targets the same clinical decision-point (timely, accurate antimicrobial therapy in suspected sepsis) addressed by Sepset-ER's risk-stratification assay.

TypeDirect peer
Description

Cytovale commercializes IntelliSep, an FDA-cleared rapid (<10 minute) biophysical sepsis test for use in hospital EDs. It competes head-to-head with Sepset-ER for the same ER triage ordering slot by offering faster time-to-result and is a direct substitute product for early sepsis risk stratification.

TypeBroad incumbent
Description

QIAGEN supplies sample-preparation technologies and molecular diagnostic kits (e.g., QIAstat-Dx) used in infectious-disease testing, including assays relevant to sepsis workups. While broader than Sepset, its installed PCR/NAAT base in hospitals makes it a comparable IVD incumbent and a candidate for technology-transfer partnerships.

TypeBroad incumbent
Description

Cepheid's GeneXpert system (owned by Danaher) is a leading molecular diagnostic platform with broad infectious-disease menu used in hospitals. It is a relevant incumbent for the same hospital sepsis-workup slot, and a natural partner for any Sepset gene-signature platform transfer onto an installed clinical instrument.

TypeBroad incumbent
Description

bioMérieux is a global IVD leader whose BioFire FilmArray BCID panels and VITEK systems are entrenched in hospital sepsis workups. While broader than Sepset-ER, BioFire is the dominant molecular alternative in the ER/ICU and a likely licensee/acquirer candidate or competitive benchmark for any host-response sepsis product.

TypeBroad incumbent
Description

BD is the dominant supplier of blood-culture instruments and bottles used in the current ~24-hour-to-three-day sepsis diagnostic standard that Sepset-ER aims to displace. The company also offers the BD MAX molecular system; it represents both a key competitor and a potential channel/licensing partner for next-generation sepsis diagnostics.

TypeBroad incumbent
Description

Roche Diagnostics operates the cobas molecular and Elecsys immunoassay platforms widely installed in hospital core labs. Its broad infectious-disease and sepsis-related menu (including procalcitonin) makes it a relevant broad-incumbent peer and potential large-ivd license partner for the Sepset gene signature.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sepset Biosciences

Molecular Diagnosticssepset.ca

Sepset Biosciences is a pre-commercial molecular diagnostics company developing the Sepset-ER blood-based gene expression assay for rapid (~1 hour) sepsis risk assessment in hospital emergency rooms and intensive care units, commercializing via out-licensing to diagnostic partners.

What Sepset Biosciences does

Sepset Biosciences Inc. is a privately held molecular diagnostics company headquartered in Victoria, British Columbia, that is developing a first-in-class blood-based in vitro diagnostic assay called Sepset-ER for early risk assessment of sepsis. The test detects a proprietary gene expression signature based on the dysfunctional immune response (cellular reprogramming, also termed endotoxin tolerance) rather than the presence of a pathogen, identifying patients at high risk of developing sepsis and associated organ failure within approximately 1-2 hours of blood draw at first clinical presentation in the emergency room or intensive care unit. The technology was discovered by Drs. Robert Hancock and Olga Pena at the University of British Columbia, patented in 18 countries (with grants confirmed in Europe, China, and Hong Kong), and validated across more than 3,000 patients in prospective multi-center international clinical studies, with the most recent validation published in Nature Communications 16(1):4442 (Malic et al., 2025).

The company's core technical components are a host-response gene-expression signature, a proprietary machine learning classifier, and a centrifugal microfluidics platform intended for bedside use. Sepset operates as a clinical-stage R&D company with 11-50 employees and a four-person executive team led by founder/CEO Dr. Robert Hancock. Its technologies have not yet received marketing authorization and are not currently available for purchase. Sepset is preparing for 510(k) regulatory clinical studies and plans to commercialize exclusively via out-licensing its gene signature to diagnostic companies that will perform the regulatory trials and market the test in their respective countries; out-licensees are already conducting trials across geographies covering roughly one third of the world's population, with Sepset retaining partial ownership and royalty rights.

Sepset was founded in 2016 as a spinout from the Centre for Drug Research and Development (CDRD, now adMare) and UBC, and is majority-owned by publicly listed parent Asep Medical Holdings Inc. (CSE). Revenue has not been disclosed and the company remains pre-commercial, addressing a market opportunity anchored by an estimated $24 billion annual U.S. cost of treating sepsis and 49 million global sepsis hospitalizations per year.

Sepset Biosciences firmographics

Firmographics
Name
Sepset Biosciences
Legal name
Sepset Biosciences Inc.
Website
https://sepset.ca
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Sepset Biosciences is a pre-commercial molecular diagnostics company developing the Sepset-ER blood-based gene expression assay for rapid (~1 hour) sepsis risk assessment in hospital emergency rooms and intensive care units, commercializing via out-licensing to diagnostic partners.
Ownership category
akta.pro rank

Sepset Biosciences industry classification

Industry
Product category
Molecular Diagnostics
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)

Keywords

  • Molecular diagnostics
  • Sepsis detection
  • Gene expression assay
  • In vitro diagnostics
  • Blood-based diagnostics

Where Sepset Biosciences is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Sepset Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Out-licensing and Royalty Agreements: Sepset has out-licensed its technology to companies performing regulatory trials and marketing the test in countries representing one third of the world's population. Sepset benefits through partial ownership of these companies and royalty agreements.
  2. In vitro Diagnostic Test Sales: Once regulatory approval is obtained, the company plans to commercialize its Sepset-ER blood-based gene expression assay through licensing partners for hospital and clinical use in ER and ICU settings.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Sepset Biosciences product offering

Product offering

Core offering

Sepset Biosciences is developing the Sepset-ER blood-based gene expression assay, a first-in-class in vitro diagnostic test that detects a unique sepsis gene expression signature based on the host's dysfunctional immune response (cellular reprogramming/endotoxin tolerance). The test provides rapid sepsis risk assessment within approximately 1-2 hours of blood sampling in emergency rooms and intensive care units, enabling earlier clinical intervention. The company plans to commercialize through out-licensing its gene signature to diagnostic companies that will perform regulatory trials and market the test.

Product overview

Sepset Biosciences is a medical diagnostic company with a single primary product offering: the Sepset-ER blood-based gene expression test. The company is in advanced development stages preparing for 510(k) regulatory clinical studies and commercialization. The test provides rapid (~1-2 hours) sepsis risk assessment by detecting a proprietary gene expression signature from blood samples, enabling physicians to make critical early treatment decisions for patients in the ER and ICU. The technology was validated on more than 3,000 patients and has been out-licensed to companies performing regulatory trials in countries representing one-third of the world's population.

Differentiator

Problem solved

Functional benefit

Brands

  • Sepset-ER: Blood-based gene expression assay test for early risk assessment of sepsis in emergency rooms and intensive care units. Provides results within approximately 1 hour after taking a blood sample.

Products and services

  • Sepset-ER Test A first-in-class blood-based gene expression assay for the early and rapid risk assessment of sepsis. The test detects a unique sepsis gene expression signature based on dysfunctional immune response (cellular reprogramming/endotoxin tolerance) to identify patients at high risk of developing sepsis and organ failure within approximately 1-2 hours of blood sampling in the emergency room or intensive care unit. The test is intended for hospital and clinical use to enable earlier intervention and reduce mortality.

Companies that use Sepset Biosciences

Customer profile

Segments1 record

Ideal customer profiles2 records

Sepset Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Sepset Biosciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Out-Licensed Diagnostic CompaniescoreOEM/ Whitelabel/ Licensing PartnerThe test has been out-licensed to companies performing regulatory trials and marketing the test in countries representing one third of the world's population. Sepset benefits through partial ownership of these companies and royalty agreements.
  • University of British Columbia (UBC)coreStrategic or Co-development PartnerSepset's technology is based on extensive ground-breaking work led by Dr. Robert Hancock, Professor of Microbiology and Immunology and Director of the Centre for Microbial Diseases and Immunity Research at UBC. The spinout was a collaboration between CDRD and UBC.
  • Dr. John Boyd (St. Paul's Hospital)minorOthersDr. John Boyd, an emergency room physician at Vancouver's St. Paul's Hospital, serves as an advisor to Sepset, providing clinical perspective on the diagnostic test's utility in real-world ER settings.
  • Diagnostic Companies (Prospective Partners)coreChannel Partner/ Reseller/ DistributorSepset welcomes opportunities to collaborate with diagnostic companies that wish to transfer its gene signature onto a clinical platform. The company actively seeks new partnerships to expand distribution of the technology.

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Sepset Biosciences competitors and assessment

Company assessment

Direct peers

  • Prenosis (formerly Inflammatix): Prenosis (which merged with Inflammatix) is developing host-response diagnostics for acute infections and sepsis, including the Sepsis ImmunoScore, leveraging AI on gene-expression and clinical biomarker data. Directly comparable to Sepset on technology category (host-response), target use case (early sepsis recognition) and go-to-market (partnership with hospital systems and IVD platforms).
  • T2 Biosystems: T2 Biosystems markets T2Bacteria and T2Candida, FDA-cleared direct-from-blood molecular diagnostics for bloodstream infections. While pathogen-detection based rather than host-response, T2 addresses the same sepsis-workup bottleneck (speed of pathogen ID vs. blood culture) and competes for the same hospital diagnostic budget.
  • Immunexpress: Immunexpress developed SeptiCyte RAPID, an FDA-cleared blood-based host-response gene-expression test that distinguishes sepsis from SIRS in ICU patients. It is the closest functional analog to Sepset-ER - same biology (host immune-response gene signature), same use case (sepsis risk stratification), and same planned customer (ER/ICU physicians).
  • Accelerate Diagnostics: Accelerate Diagnostics develops rapid identification and antimicrobial susceptibility testing (ID/AST) systems for bloodstream and other serious infections. Its Accelerate Pheno system targets the same clinical decision-point (timely, accurate antimicrobial therapy in suspected sepsis) addressed by Sepset-ER's risk-stratification assay.
  • Cytovale: Cytovale commercializes IntelliSep, an FDA-cleared rapid (<10 minute) biophysical sepsis test for use in hospital EDs. It competes head-to-head with Sepset-ER for the same ER triage ordering slot by offering faster time-to-result and is a direct substitute product for early sepsis risk stratification.

Broad incumbents

  • QIAGEN: QIAGEN supplies sample-preparation technologies and molecular diagnostic kits (e.g., QIAstat-Dx) used in infectious-disease testing, including assays relevant to sepsis workups. While broader than Sepset, its installed PCR/NAAT base in hospitals makes it a comparable IVD incumbent and a candidate for technology-transfer partnerships.
  • Cepheid (Danaher): Cepheid's GeneXpert system (owned by Danaher) is a leading molecular diagnostic platform with broad infectious-disease menu used in hospitals. It is a relevant incumbent for the same hospital sepsis-workup slot, and a natural partner for any Sepset gene-signature platform transfer onto an installed clinical instrument.
  • bioMérieux: bioMérieux is a global IVD leader whose BioFire FilmArray BCID panels and VITEK systems are entrenched in hospital sepsis workups. While broader than Sepset-ER, BioFire is the dominant molecular alternative in the ER/ICU and a likely licensee/acquirer candidate or competitive benchmark for any host-response sepsis product.
  • Becton, Dickinson and Company (BD): BD is the dominant supplier of blood-culture instruments and bottles used in the current ~24-hour-to-three-day sepsis diagnostic standard that Sepset-ER aims to displace. The company also offers the BD MAX molecular system; it represents both a key competitor and a potential channel/licensing partner for next-generation sepsis diagnostics.
  • Roche Diagnostics: Roche Diagnostics operates the cobas molecular and Elecsys immunoassay platforms widely installed in hospital core labs. Its broad infectious-disease and sepsis-related menu (including procalcitonin) makes it a relevant broad-incumbent peer and potential large-ivd license partner for the Sepset gene signature.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Sepset Biosciences social profiles

Digital presence

Sepset Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sepset Biosciences leadership team

Management profile

Number of profiles

Profiles4 records

Sepset Biosciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sepset Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sepset Biosciences

What does Sepset Biosciences do?

Sepset Biosciences is developing the Sepset-ER blood-based gene expression assay, a first-in-class in vitro diagnostic test that detects a unique sepsis gene expression signature based on the host's dysfunctional immune response (cellular reprogramming/endotoxin tolerance). The test provides rapid sepsis risk assessment within approximately 1-2 hours of blood sampling in emergency rooms and intensive care units, enabling earlier clinical intervention. The company plans to commercialize through out-licensing its gene signature to diagnostic companies that will perform regulatory trials and market the test.

Is Sepset Biosciences a public or private company?

Sepset Biosciences is a private company. It is classified as corporate owned and is currently operating.

When was Sepset Biosciences founded?

Sepset Biosciences was founded in 2016. It employs 11 to 50 people.

Where is Sepset Biosciences based?

Sepset Biosciences is headquartered in Vancouver, Canada, in the North America region.

How does Sepset Biosciences make money?

Two revenue lines are on record. Out-licensing and Royalty Agreements are the primary driver. The others are in vitro Diagnostic Test Sales.

Who are Sepset Biosciences's main competitors?

Direct peers on record are Prenosis (formerly Inflammatix), T2 Biosystems, Immunexpress, Accelerate Diagnostics and Cytovale. Broad incumbents are QIAGEN, Cepheid (Danaher), bioMérieux, Becton, Dickinson and Company (BD) and Roche Diagnostics.

Does Sepset Biosciences have an API?

No public API is recorded for Sepset Biosciences.

What industry is Sepset Biosciences in?

Sepset Biosciences's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals